TY - JOUR
T1 - Bacterial Specific Recognition of Sulfonium Poly(Amino Acid) Adsorbents for Ultrafast MRSA Capture Against Bloodstream Infection
AU - Zhang, Zhenyan
AU - Wang, Lei
AU - Yu, Qing
AU - Li, Jing
AU - Li, Peng
AU - Luan, Shifang
AU - Shi, Hengchong
N1 - Publisher Copyright:
© 2025 Wiley-VCH GmbH.
PY - 2025
Y1 - 2025
N2 - Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections pose significant health risks, potentially leading to severe conditions such as bacteremia. Developing effective treatments to eliminate resistant bacteria from the bloodstream, simultaneously mitigate infection-related complications, and reduce mortality remains challenging. Herein, microspheres are synthesized with bacterial elimination and inflammation prevention by crosslinked sulfonium poly(amino acids). As-synthesized microsphere, PM10.6B MS, exhibits an ultrafast adsorption efficiency of 0.41 × 108 CFU mg−1 min−1 for MRSA, which positions the highest index among the reported resin and inorganic adsorptions. This bacterial-specific and efficient capture of PM10.6B MS is attributed to its strong interactions with teichoic acids in MRSA (Ka: 1.8 × 105 M−1) rather than acting with phospholipids of mammalian cells. Unlike the present resin-based adsorbent, for example, heparin-modified polyethylene in the only commercial Seraph® 100, PM10.6B MS kills adsorbed bacteria within 1 h and can be reused by simple treatment. Meanwhile, PM10.6B MS also shows good hemocompatibility and longer thrombin activation time to reduce the risk of thrombosis and hemolysis. In vivo experiments further confirm the abilities of PM10.6B MS to prevent inflammation by removing bacteria. This adsorbent is a promising candidate for early treating life-threatening bloodstream infections, potentially preventing bacteremia and subsequent organ damage.
AB - Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections pose significant health risks, potentially leading to severe conditions such as bacteremia. Developing effective treatments to eliminate resistant bacteria from the bloodstream, simultaneously mitigate infection-related complications, and reduce mortality remains challenging. Herein, microspheres are synthesized with bacterial elimination and inflammation prevention by crosslinked sulfonium poly(amino acids). As-synthesized microsphere, PM10.6B MS, exhibits an ultrafast adsorption efficiency of 0.41 × 108 CFU mg−1 min−1 for MRSA, which positions the highest index among the reported resin and inorganic adsorptions. This bacterial-specific and efficient capture of PM10.6B MS is attributed to its strong interactions with teichoic acids in MRSA (Ka: 1.8 × 105 M−1) rather than acting with phospholipids of mammalian cells. Unlike the present resin-based adsorbent, for example, heparin-modified polyethylene in the only commercial Seraph® 100, PM10.6B MS kills adsorbed bacteria within 1 h and can be reused by simple treatment. Meanwhile, PM10.6B MS also shows good hemocompatibility and longer thrombin activation time to reduce the risk of thrombosis and hemolysis. In vivo experiments further confirm the abilities of PM10.6B MS to prevent inflammation by removing bacteria. This adsorbent is a promising candidate for early treating life-threatening bloodstream infections, potentially preventing bacteremia and subsequent organ damage.
KW - MRSA clearance
KW - adsorption mechanism
KW - hemocompatibility
KW - poly(amino acid) microspheres
KW - sulfonium
UR - http://www.scopus.com/inward/record.url?scp=105002458892&partnerID=8YFLogxK
U2 - 10.1002/smll.202501298
DO - 10.1002/smll.202501298
M3 - 文章
AN - SCOPUS:105002458892
SN - 1613-6810
JO - Small
JF - Small
ER -